Immuneering Corporation Operating Income
Immuneering Corporation (IMRX) reported Operating Income of -$19.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-05
- Immuneering Corporation operating income (loss) for the quarter ending 2026-06-30 was -$19.00M.
- Immuneering Corporation operating income (loss) for the quarter ending 2026-03-31 was -$15.34M.
- Immuneering Corporation operating income (loss) for the quarter ending 2025-12-31 was -$13.75M.
- Immuneering Corporation operating income (loss) for the quarter ending 2025-09-30 was -$15.38M.
- Immuneering Corporation operating income (loss) for fiscal 2025 was -$59.38M.
- Immuneering Corporation operating income (loss) for fiscal 2024 was -$64.07M.
- Immuneering Corporation operating income (loss) for fiscal 2023 was -$58.41M.
- Immuneering Corporation operating income (loss) for fiscal 2022 was -$51.74M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$19.00M 10-Q · filed 2026-08-05 | -$34.34M 10-Q · filed 2026-08-05 | -$48.09M derived: sum of 3 quarters · filed 2026-08-05 | -$63.47M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$15.34M 10-Q · filed 2026-05-15 | -$29.09M derived: sum of 2 quarters · filed 2026-05-15 | -$44.47M derived: sum of 3 quarters · filed 2026-05-15 | -$59.23M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$13.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$29.13M derived: sum of 2 quarters · filed 2026-03-06 | -$43.89M derived: sum of 3 quarters · filed 2026-08-05 | -$59.38M 10-K · filed 2026-03-06 |
| 2025-09-30 | -$15.38M 10-Q · filed 2025-11-12 | -$30.14M derived: sum of 2 quarters · filed 2026-08-05 | -$45.62M 10-Q · filed 2025-11-12 | -$64.18M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$14.76M 10-Q · filed 2026-08-05 | -$30.24M 10-Q · filed 2026-08-05 | -$48.80M derived: sum of 3 quarters · filed 2026-08-05 | -$64.07M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$15.48M 10-Q · filed 2026-05-15 | -$34.04M derived: sum of 2 quarters · filed 2026-05-15 | -$49.32M derived: sum of 3 quarters · filed 2026-05-15 | -$64.23M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$18.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$33.83M derived: sum of 2 quarters · filed 2026-03-06 | -$48.75M derived: sum of 3 quarters · filed 2026-03-06 | -$64.07M 10-K · filed 2026-03-06 |
| 2024-09-30 | -$15.27M 10-Q · filed 2025-11-12 | -$30.19M derived: sum of 2 quarters · filed 2025-11-12 | -$45.51M 10-Q · filed 2025-11-12 | -$61.82M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$14.91M 10-Q · filed 2025-08-13 | -$30.24M 10-Q · filed 2025-08-13 | -$46.54M derived: sum of 3 quarters · filed 2025-08-13 | -$60.47M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$15.33M 10-Q · filed 2025-05-05 | -$31.63M derived: sum of 2 quarters · filed 2025-05-05 | -$45.55M derived: sum of 3 quarters · filed 2025-05-05 | -$59.06M derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | -$16.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$30.23M derived: sum of 2 quarters · filed 2025-03-20 | -$43.73M derived: sum of 3 quarters · filed 2025-03-20 | -$58.41M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$13.93M 10-Q · filed 2024-11-13 | -$27.43M derived: sum of 2 quarters · filed 2024-11-13 | -$42.11M 10-Q · filed 2024-11-13 | -$56.10M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$13.50M 10-Q · filed 2024-08-06 | -$28.18M 10-Q · filed 2024-08-06 | -$42.17M derived: sum of 3 quarters · filed 2024-08-06 | -$55.36M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$14.68M 10-Q · filed 2024-05-07 | -$28.66M derived: sum of 2 quarters · filed 2024-05-07 | -$41.85M derived: sum of 3 quarters · filed 2024-05-07 | -$53.50M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$13.99M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | -$27.17M derived: sum of 2 quarters · filed 2024-03-01 | -$38.82M derived: sum of 3 quarters · filed 2024-03-01 | -$51.74M 10-K · filed 2024-03-01 |
| 2022-09-30 | -$13.19M 10-Q · filed 2023-11-09 | -$24.83M derived: sum of 2 quarters · filed 2023-11-09 | -$37.76M 10-Q · filed 2023-11-09 | -$48.88M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$11.65M 10-Q · filed 2023-08-03 | -$24.57M 10-Q · filed 2023-08-03 | -$35.69M derived: sum of 3 quarters · filed 2023-08-03 | -$44.23M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$12.93M 10-Q · filed 2023-05-04 | -$24.04M derived: sum of 2 quarters · filed 2023-05-04 | -$32.58M derived: sum of 3 quarters · filed 2023-05-04 | -$40.58M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$11.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$19.66M derived: sum of 2 quarters · filed 2023-03-06 | -$27.65M derived: sum of 3 quarters · filed 2023-03-06 | -$33.89M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$8.54M 10-Q · filed 2022-11-10 | -$16.53M derived: sum of 2 quarters · filed 2022-11-10 | -$22.77M 10-Q · filed 2022-11-10 | -$28.61M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$7.99M 10-Q · filed 2022-08-10 | -$14.23M 10-Q · filed 2022-08-10 | -$20.06M derived: sum of 3 quarters · filed 2022-08-10 | -$24.46M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$6.24M 10-Q · filed 2022-05-10 | -$12.07M derived: sum of 2 quarters · filed 2022-05-10 | -$16.47M derived: sum of 3 quarters · filed 2022-05-10 | -$20.08M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$5.84M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$10.24M derived: sum of 2 quarters · filed 2022-03-10 | -$13.84M derived: sum of 3 quarters · filed 2022-03-10 | -$17.08M 10-K · filed 2022-03-10 |
| 2020-09-30 | -$4.40M 10-Q · filed 2021-11-09 | -$8.01M derived: sum of 2 quarters · filed 2021-11-09 | -$11.25M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$3.61M 10-Q · filed 2021-09-09 | -$6.85M 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |